{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:01Z","timestamp":1790790181220,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the accumulation of transthyretin (TTR) protein in the myocardium. The aim of this scoping review is to provide a descriptive summary of the clinical trials and observational studies that evaluated the clinical efficacy and safety of various agents used in ATTR-CM, with a goal of identifying the contemporary gaps in literature and to reveal future research opportunities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The search was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search using several databases for observational and clinical trials investigating the treatment modalities for ATTR-CM was undertaken. We extracted data including study characteristics, primary endpoints, and adverse events from each study. A total of 19 studies were included in our scoping review. Out of which, 8 were clinical trials and 11 were observational analyses. The drugs evaluated included tafamadis, acoramidis, revusiran, doxycycline and tauroursodeoxycholic acid and doxycycline, diflusinil, inotersan, eplontersen, and patisiran. Tafamidis has shown to be efficacious in the management of ATTR-CM, particularly when initiated at earlier stages. RNA interference and antisense oligonucleotide drugs have shown promising impacts on quality of life. Additionally, this review identified gaps in the literature, particularly among long-term outcomes, comparative effectiveness, and the translation of research into economic contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Multiple pharmacological options are potential disease-modifying therapies for ATTR-CM. However, many gaps exist in the understanding of these various drug therapies, warranting further research. The future directions for management of ATTR-CM are promising in regard to improving prognostic implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae044","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T01:35:13Z","timestamp":1717292113000},"page":"547-556","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review"],"prefix":"10.1093","volume":"10","author":[{"given":"Shafi","family":"Rehman","sequence":"first","affiliation":[{"name":"D , Road No. 2, University of Rd No. 2, Rahat Abad, Peshawar, Khyber Pakhtunkhwa 25120 ,","place":["Pakistan"]},{"name":"epartment of Histopathology, Khyber Medical University , Road No. 2, University of Rd No. 2, Rahat Abad, Peshawar, Khyber Pakhtunkhwa 25120 ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameera Shaik","family":"Masthan","sequence":"additional","affiliation":[{"name":"Seattle Medical Post-Acute Care , 555 16th Ave, Seattle, WA 98122 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-9513","authenticated-orcid":false,"given":"Ramzi","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona-Banner University Medical Center , 1625 N Campbell Ave, Tucson, AZ 85719 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Nhat","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona-Banner University Medical Center , 1625 N Campbell Ave, Tucson, AZ 85719 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danial","family":"Hassan","sequence":"additional","affiliation":[{"name":"Harvard TH Chan School of Public Health , 677 Huntington Ave, Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Sindh Institute of Urology and Transplantation , Chand Bibi Rd, Ranchore Lane, Karachi, Karachi City, Sindh ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shahzad","family":"Asif","sequence":"additional","affiliation":[{"name":"Department of Medicine, University College of Medicine and Dentistry , Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Safdar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cleveland Clinic , 9500 Euclid Ave, Cleveland, OH 44195 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Anwar","sequence":"additional","affiliation":[{"name":"University School , Health Education Campus, 9501 Euclid Ave, Cleveland, OH 44106 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"Taussig Cancer Center, Cleveland Clinic , 10201 Carnegie Ave, Cleveland, OH 44106 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"William","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic , 9500 Euclid Ave, Cleveland, OH 44195 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"2024100407354013200_bib1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2024100407354013200_bib2","doi-asserted-by":"crossref","first-page":"102057","DOI":"10.1016\/j.cpcardiol.2023.102057","article-title":"Exploring transthyretin amyloid cardiomyopathy: a comprehensive review of the disease and upcoming treatments","volume":"49","author":"Jain","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2024100407354013200_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis Manag"},{"key":"2024100407354013200_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"key":"2024100407354013200_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (Inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals"},{"key":"2024100407354013200_bib6","first-page":"519","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ: Heart Fail"},{"key":"2024100407354013200_bib7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2024100407354013200_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2024100407354013200_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Castano","year":"2012","journal-title":"Congestive Heart Failure"},{"key":"2024100407354013200_bib10","first-page":"e004769","article-title":"TTR (Transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ: Heart Fail"},{"key":"2024100407354013200_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","article-title":"Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience","volume":"25","author":"Ikram","year":"2018","journal-title":"Amyloid"},{"key":"2024100407354013200_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J Card Fail"},{"key":"2024100407354013200_bib13","first-page":"580","article-title":"Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy","volume":"3","author":"Falk","year":"2021","journal-title":"JACC: CardioOncology"},{"key":"2024100407354013200_bib14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early experience of Tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ J"},{"key":"2024100407354013200_bib15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024100407354013200_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024100407354013200_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40256-022-00526-9","article-title":"Annual cardiovascular-related hospitalization days avoided with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"22","author":"Rozenbaum","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"2024100407354013200_bib18","doi-asserted-by":"crossref","first-page":"101667","DOI":"10.1016\/j.cpcardiol.2023.101667","article-title":"Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure","volume":"48","author":"Ghoneem","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2024100407354013200_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024100407354013200_bib20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2024100407354013200_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","article-title":"Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis","volume":"25","author":"Karlstedt","year":"2019","journal-title":"J Card Fail"},{"key":"2024100407354013200_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"2024100407354013200_bib23","first-page":"00894","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","author":"Masri","year":"2023","journal-title":"J Card Fail"},{"key":"2024100407354013200_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane","year":"2017","journal-title":"Amyloid"},{"key":"2024100407354013200_bib25","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"2024100407354013200_bib26","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"2024100407354013200_bib27","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2024100407354013200_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, Vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharma Ther"},{"key":"2024100407354013200_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"2024100407354013200_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"2024100407354013200_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2024100407354013200_bib32","article-title":"Landmark CRISPR trial shows promise against deadly disease","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"2024100407354013200_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"2024100407354013200_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae044\/58809050\/pvae044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/6\/547\/59582047\/pvae044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/6\/547\/59582047\/pvae044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T03:36:44Z","timestamp":1728013004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/6\/547\/7687153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,10,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae044","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,6,3]]}}}